Masahiro Tsuboi, MD, discusses the key takeaways from the findings for osimertinib in patients with early-stage EGFR-mutant non–small cell lung cancer following a complete tumor resection in the phase 3 ADAURA clinical trial.
Masahiro Tsuboi, MD, a surgeon at Japan’s National Cancer Center Hospital East, discusses the key takeaways from the findings for osimertinib (Tagrisso) in patients with early-stage EGFR-mutant non–small cell lung cancer (NSCLC) following a complete tumor resection in the phase 3 ADAURA clinical trial (NCT02511106), which were presented during the 2020 European Society for Medical Oncology (ESMO) Virtual Congress.
According to these results, adjuvant osimertinib demonstrated a clinically meaningful improvement in central nervous system disease-free survival compared with placebo. Treatment with osimertinib following complete tumor resection reduced the risk for central nervous system death or progression by 82%. Tsuboi says low rates of recurrence, particularly in the brain, were also observed in the study.
Based on the findings from this study, adjuvant osimertinib would be an effective and practice-changing treatment approach for patients with early-stage EGFR-mutant NSCLC.
Cretostimogene Grenadenorepvec Shows High CR Rate in BCG-Unresponsive NMIBC
July 17th 2024Mark D. Tyson, II, MD, MPH, discussed treatment with cretostimogene grenadenorepvec in high-risk Bacillus Calmette-Guérin-unresponsive non-muscle invasive bladder cancer with carcinoma in situ and data from the BOND-003 trial.
Read More
Examining Breast Cancer Recurrence Detection Methods in a Community Oncology Setting
July 12th 2024In an interview with Targeted Oncology, Ali Duffens, MD, discussed findings from a study which investigated detecting breast cancer recurrence among women treated at Kaiser Permanente Northern California.
Read More